Levels of bioactive adrenomedullin in plasma and cerebrospinal fluid in relation to delayed cerebral ischemia in patients after aneurysmal subarachnoid hemorrhage: A prospective observational study

What Was Tested

Researchers studied Adrenomedullin in this observational study publication.

A recently developed assay specific for bioactive adrenomedullin (bio-ADM) has not yet been assessed in aneurysmal subarachnoid hemorrhage (aSAH).

The objective of this prospective trial was to assess the time course of bio-ADM after aSAH in relation to the development of delayed cerebral ischemia (DCI) and its association with clinical outcome.

Who Took Part

The study group was 30 patients.

Bio-ADM levels in plasma and cerebrospinal fluid (CSF) were measured during five predefined epochs, for up to 21 days in 30 aSAH patients: early, (day 0 to day 3); acute, (day 4 to day 8); early critical, (day 9 to day 12); late critical, (day 13 to day 15), and late (day 16 to day 21).

How the Study Was Run

The methods mention a period of 21 days.

DCI was diagnosed clinically or based on multimodal monitoring and imaging, and the occurrence of DCI-related cerebral infarction, and outcome after 12 months (extended Glasgow outcome scale), was noted.

What Was Measured

Topics PubMed links to this paper include Adrenomedullin, Brain Ischemia, Cerebral Infarction and Subarachnoid Hemorrhage.

Author keywords: Delayed cerebral infarction, Delayed cerebral ischemia and Stroke.

What This Means in Plain Language

This is a observational study of Adrenomedullin in 30 patients over 21 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Journal of the neurological sciences), a journal based in Netherlands.

More context: the Adrenomedullin compound page, all human trials.